CytomX Therapeutics, Inc. is a privately-funded biotechnology company developing highly targeted antibody therapeutics. Our novel, proprietary Probody™ Platform delivers antibodies that achieve unprecedented levels of diseased tissue-specific targeting. Probodies are a unique class of fully recombinant, protease-activated monoclonal antibodies designed to leverage protease dysregulation within disease microenvironments, a hallmark of many pathologies. Probodies expand the therapeutic index for targets with validated disease biology but with normal tissue expression patterns that are too widespread to allow for adequate safety margins. This highly innovative platform is broadly enabling to all common antibody formats including bispecifics, multispecifics and antibody-drug conjugates.
Our novel platform represents a transformational drug discovery and development approach. CytomX is driving the development of a pipeline of Probody therapeutics directed against a portfolio of promising targets and pathways that have been limited by safety challenges, together with clinically and commercially validated targets for which severe toxicities have limited full commercial potential.
Read our Latest News.
